|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The treated tumors overexpressed the glutamate/cystine antiporter SLC7A11/ xCT which led to elevated extracellular glutamate in these tumors.
|
31723000 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, IFNγ derived from immunotherapy-activated CD8<sup>+</sup> T cells and radiotherapy-activated ATM independently, yet synergistically, suppresses SLC7A11, a unit of the glutamate-cystine antiporter xc<sup>-</sup>, resulting in reduced cystine uptake, enhanced tumor lipid oxidation and ferroptosis, and improved tumor control.
|
31554642 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
OTUB1 was overexpressed in human cancers, and inactivation of OTUB1 destabilized SLC7A11 and led to growth suppression of tumor xenografts in mice, which was associated with reduced activation of ferroptosis.
|
30709928 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.
|
31444923 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, interferon gamma (IFNγ) released from CD8<sup>+</sup> T cells downregulates the expression of SLC3A2 and SLC7A11, two subunits of the glutamate-cystine antiporter system x<sub>c</sub><sup>-</sup>, impairs the uptake of cystine by tumour cells, and as a consequence, promotes tumour cell lipid peroxidation and ferroptosis.
|
31043744 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
More significantly, The over-accumulated intracellular ROS, increased O<sub>2</sub> concentration and inhibited SLC7A11 expression lead to enhanced toxicity to CAL-27 cells and satisfactory antitumor effects to xenograft tumour mouse model upon irradiation.
|
31244955 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we show that BAP1 inhibits tumour development partly through SLC7A11 and ferroptosis, and that cancer-associated BAP1 mutants lose their abilities to repress SLC7A11 and to promote ferroptosis.
|
30202049 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of tumor microarray PCa tissues (N = 165) with high Gleason scores indicated that xCT protein expression is significantly increased while ECSOD protein expression is significantly decreased.
|
29421238 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, activation of the Nrf2-Keap1 signaling upregulates xCT (aka SLC7A11 or system X<sub>c</sub><sup>-</sup>) and amplifies glutamate secretion thereby impacting on the tumor microenvironment.
|
28805788 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data demonstrate the tumor suppressor role of As-SLC7A11 in ovarian cancer malignancies.
|
29441937 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC7A11-AS1, antisense to SLC7A11, is significantly down-regulated in gastric cancer and could promote tumor growth <i>in vitro</i> and <i>in vivo</i>.
|
29348845 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SLC7A11 is highly expressed in human tumours, and its overexpression inhibits ROS-induced ferroptosis and abrogates p53(3KR)-mediated tumour growth suppression in xenograft models.
|
25799988 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma.
|
24708874 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients, SLC7A11 expression was inversely related to miRNA-27a expression, and those tumors with high mRNA expression or high membrane staining for SLC7A11 experienced poorer clinical outcomes.
|
24516043 |
2014 |